Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $134.3 million.

  • Haemonetics' Other Accumulated Expenses fell 352.35% to $134.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $134.3 million, marking a year-over-year decrease of 352.35%. This contributed to the annual value of $148.1 million for FY2025, which is 885.09% up from last year.
  • According to the latest figures from Q4 2025, Haemonetics' Other Accumulated Expenses is $134.3 million, which was down 352.35% from $134.0 million recorded in Q3 2025.
  • Haemonetics' Other Accumulated Expenses' 5-year high stood at $150.0 million during Q3 2024, with a 5-year trough of $85.3 million in Q3 2022.
  • In the last 5 years, Haemonetics' Other Accumulated Expenses had a median value of $130.1 million in 2021 and averaged $125.9 million.
  • As far as peak fluctuations go, Haemonetics' Other Accumulated Expenses soared by 4193.42% in 2021, and later tumbled by 3325.69% in 2022.
  • Haemonetics' Other Accumulated Expenses (Quarter) stood at $119.7 million in 2021, then dropped by 15.63% to $101.0 million in 2022, then skyrocketed by 31.12% to $132.4 million in 2023, then grew by 5.15% to $139.2 million in 2024, then dropped by 3.52% to $134.3 million in 2025.
  • Its last three reported values are $134.3 million in Q4 2025, $134.0 million for Q3 2025, and $145.6 million during Q2 2025.